Recently, Shandong Yingsheng Biotechnology Co., Ltd. completed Series B financing of several hundred million yuan, which was led by Gaochun Venture Capital. Old shareholders such as Chenling Capital, Sunshine Ronghui Capital, Huimei Capital and Qianhai Parent Fund continued to raise funds, Yuansheng Venture Capital and Haoyue Capital acted as the exclusive financial advisor.
Earlier, the company was invested by famous institutions such as Sanze Venture Capital, Yahui Investment and Xiamen Jianfa. After the completion of this round of financing, Yingsheng Bio plans to accelerate the market expansion in the field of mass spectrometry, consolidate the industrial chain and technical team, maintain the leading edge in product development, and on this basis, build a full range of products for clinical mass spectrometry applications and shape IVD brand enterprises.
Yingsheng Bio, established in 2009, is a pioneer in technology development, quality control and technical services in the field of clinical mass spectrometry in China, focusing on the field of clinical mass spectrometry for more than ten years, and is also a high-tech enterprise integrating R&D, production, sales and third-party medical testing services.
Yingsheng built a leading domestic gene detection platform and mass spectrometry detection platform around metabonomics and genomics, covering the fields of birth defect screening, disease prevention and human health services, and won 15 national patents and 6 software copyrights, participated in the construction of 3 industry standards and 1 national standard, and passed ISO13485 and ISO9001 quality management system certification. It is the backbone enterprise of the key biomedical engineering industrial cluster in the "13 th Five-Year Plan" of science and technology innovation in Shandong Province.
Yingsheng will use the fresh funding to develop its clinical mass spectrometry technology. Located at East China’s Jinan city, the 11-year-old Yingsheng leverages its gene detection and mass spectrometry detection platform to produce genealogy-based medical testing tools and services. The solutions are widely used across birth defect screening and disease prevention. Its early-stage investors also include Sunz Fund, Alwin Capital, and Source Capital.
Gaorong Capital is a venture capital firm that focuses on early and growth stage investments in TMT, including AI and frontier technologies.